B. Riley Has Negative Outlook for InfuSystem FY2024 Earnings

InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) - Analysts at B. Riley decreased their FY2024 EPS estimates for InfuSystem in a research note issued to investors on Thursday, November 7th. B. Riley analyst K. Bauser now expects that the company will post earnings of $0.15 per share for the year, down from their previous forecast of $0.17. B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for InfuSystem's current full-year earnings is $0.15 per share. B. Riley also issued estimates for InfuSystem's Q4 2024 earnings at $0.08 EPS, Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.06 EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at $0.31 EPS and FY2026 earnings at $0.43 EPS.

Separately, StockNews.com upgraded shares of InfuSystem from a "buy" rating to a "strong-buy" rating in a research note on Friday.

InfuSystem Stock Performance

Shares of InfuSystem stock traded up $1.30 on Monday, reaching $9.11. The stock had a trading volume of 313,552 shares, compared to its average volume of 58,393. The business has a 50-day moving average price of $6.59. The company has a current ratio of 2.07, a quick ratio of 1.64 and a debt-to-equity ratio of 0.64. InfuSystem has a fifty-two week low of $5.74 and a fifty-two week high of $10.99. The company has a market capitalization of $194.23 million, a PE ratio of 144.19 and a beta of 1.45.

InfuSystem (NYSE:INFU - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.01). InfuSystem had a return on equity of 2.82% and a net margin of 1.12%. The firm had revenue of $33.70 million during the quarter.

Hedge Funds Weigh In On InfuSystem

Several large investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in InfuSystem by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 1,083,730 shares of the company's stock valued at $9,288,000 after buying an additional 18,432 shares during the period. Sequoia Financial Advisors LLC bought a new stake in InfuSystem in the 2nd quarter valued at $272,000. First Eagle Investment Management LLC increased its holdings in InfuSystem by 12.7% in the 1st quarter. First Eagle Investment Management LLC now owns 605,235 shares of the company's stock valued at $5,187,000 after buying an additional 68,021 shares during the period. Bank of New York Mellon Corp increased its holdings in InfuSystem by 6.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 93,899 shares of the company's stock valued at $641,000 after buying an additional 5,391 shares during the period. Finally, Oppenheimer Asset Management Inc. increased its holdings in InfuSystem by 52.1% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 26,042 shares of the company's stock valued at $178,000 after buying an additional 8,917 shares during the period. 71.13% of the stock is currently owned by institutional investors and hedge funds.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.